The relevant role of immunotherapy (anti-PD1/anti-PD-L1) in the treatment of patients with NSCLC and advanced disease has been clearly demonstrated in several randomized phase III studies published in recent years. The gene discussed is RPL17; the disease is non-small cell lung carcinoma.